Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Research Institute for Future Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Anticancer Res. 2024 Oct;44(10):4273-4282. doi: 10.21873/anticanres.17257.
BACKGROUND/AIM: Epithelial ovarian cancer (EOC) is a lethal disease that is the fifth leading cause of cancer-related death in women. BAF312 (siponimod) is a potent and selective sphingosine-1-phosphate (S1P) receptor modulator that has been approved as a treatment for multiple sclerosis. In addition to its immunomodulatory action, BAF312 shows preclinical antitumor effects in several cancer types. This study sought to determine whether BAF312 had anticancer properties against EOC using in vitro and in vivo models.
EOC cell lines A2780, SKOV3ip1, A2780-CP20, and SKOV3-TR were treated with BAF312 and tested for cell proliferation, apoptosis, and migration using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, fluorescence-activated cell sorting, and migration assays. We investigated the expression of sphingosine-1-phosphate receptor 1 (S1PR1) in most EOC cell lines through western blot analysis. To investigate potential mechanisms, western blot analysis was used to assess the expression of AKT serine/threonine kinase 1 (AKT) and extracellular-regulated kinase (ERK) after BAF312 treatment. We also created poly(D,L-lactide-co-glycolide) nanoparticles encapsulating BAF312 (PLGA-NP-BAF312) for in vivo therapy. The average size and zeta potential of PLGA-NP-BAF312 were determined using dynamic light scattering. The therapeutic efficacy of PLGA-NP-BAF312 was tested in an A2780 tumor-bearing orthotopic mouse model of EOC.
S1PR1 was overexpressed in most EOC cell lines. BAF312 significantly reduced cell proliferation and migration while inducing significant apoptosis in all EOC cell lines. PLGA-NP-BAF312 treatment significantly reduced tumor weights in A2780 tumor-bearing mice. Furthermore, the anticancer effects of BAF312 were associated with reduced phosphorylation of ERK and AKT.
Our findings show that BAF312 has significant anticancer effects in EOC cells by inhibiting the ERK and AKT pathways, and might potentially be used to treat EOCs.
背景/目的:上皮性卵巢癌(EOC)是一种致命疾病,是女性癌症相关死亡的第五大主要原因。BAF312(西尼莫德)是一种有效的、选择性的鞘氨醇-1-磷酸(S1P)受体调节剂,已被批准用于治疗多发性硬化症。除了其免疫调节作用外,BAF312 在几种癌症类型中显示出临床前抗肿瘤作用。本研究旨在使用体外和体内模型确定 BAF312 对 EOC 是否具有抗癌特性。
用 BAF312 处理 EOC 细胞系 A2780、SKOV3ip1、A2780-CP20 和 SKOV3-TR,并使用 3-(4,5-二甲基噻唑-2-基)-2,5-二苯基四唑溴盐、荧光激活细胞分选和迁移试验检测细胞增殖、凋亡和迁移。我们通过 Western blot 分析研究了大多数 EOC 细胞系中鞘氨醇-1-磷酸受体 1(S1PR1)的表达。为了研究潜在的机制,我们使用 Western blot 分析评估了 BAF312 处理后 AKT 丝氨酸/苏氨酸激酶 1(AKT)和细胞外调节激酶(ERK)的表达。我们还创建了包封 BAF312 的聚(D,L-乳酸-co-乙醇酸)纳米粒(PLGA-NP-BAF312)用于体内治疗。使用动态光散射法测定 PLGA-NP-BAF312 的平均粒径和 Zeta 电位。在 EOC 的 A2780 荷瘤原位小鼠模型中测试了 PLGA-NP-BAF312 的治疗效果。
S1PR1 在大多数 EOC 细胞系中过表达。BAF312 显著降低了所有 EOC 细胞系的细胞增殖和迁移能力,同时诱导了显著的细胞凋亡。PLGA-NP-BAF312 治疗显著降低了 A2780 荷瘤小鼠的肿瘤重量。此外,BAF312 的抗癌作用与 ERK 和 AKT 磷酸化减少有关。
我们的研究结果表明,BAF312 通过抑制 ERK 和 AKT 通路对 EOC 细胞具有显著的抗癌作用,可能有潜力用于治疗 EOC。